
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical is a positive investment due to their recent high-level commercial execution, strong turnaround strategy and progress, and potential financial impact from recent agreements - including the potential for "meaningful commercial revenue in 2028." In addition, their focus on expense management and business transformation should lead to improved profitability. While there are risks to achieving the target price, we arrived at our target by attaching a 20x multiple to FY/26 adjusted EBITDA estimate and risk factors such as failure to meet revenue or earnings estimates.
Bears say
Lifecore Biomedical is seeing impressive growth opportunities through capacity utilization, demonstrating strong execution of the strategic vision of CEO Paul Josephs and his team. Despite historical limitations in its business scope, Lifecore is now expanding to reach a larger vision. However, there are risks, such as failure to meet revenue or earnings estimates, that may impact achieving projected price targets. The use of EV/EBITDA as a pricing metric also presents potential uncertainties.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares